The properties of bovine spongiform encephalopathy (BSE) and variant Creutzfeldt-Jakob disease (vCJD) prions are faithfully maintained upon transmission to guinea pigs. However, primary and secondary transmissions of BSE and vCJD in guinea pigs result in long incubation periods of ϳ450 and ϳ350 days, respectively. To determine if the incubation periods of BSE and vCJD prions could be shortened, we generated transgenic (Tg) mice expressing guinea pig prion protein (GPPrP). Inoculation of Tg(GPPrP) mice with BSE and vCJD prions resulted in mean incubation periods of 210 and 199 days, respectively, which shortened to 137 and 122 days upon serial transmission. In contrast, three different isolates of sporadic CJD prions failed to transmit disease to Tg(GPPrP mice). Many of the strain-specified biochemical and neuropathological properties of BSE and vCJD prions, including the presence of type 2 protease-resistant PrP Sc , were preserved upon propagation in Tg(GPPrP) mice. Structural modeling revealed that two residues near the N-terminal region of ␣-helix 1 in GPPrP might mediate its susceptibility to BSE and vCJD prions. Our results demonstrate that expression of GPPrP in Tg mice supports the rapid propagation of BSE and vCJD prions and suggest that Tg(GPPrP) mice may serve as a useful paradigm for bioassaying these prion isolates.
P rions are self-propagating, ␤-sheet-rich protein aggregates that play a central role in many human neurodegenerative diseases (1, 2) . Disorders such as Creutzfeldt-Jakob disease (CJD) in humans, chronic wasting disease in deer and elk, scrapie in sheep, and bovine spongiform encephalopathy (BSE) are caused by the accumulation of prions composed of an alternatively folded and infectious conformer of the prion protein (PrP) in the brain (3, 4) . Prion diseases can also be zoonotic, as in the case of variant CJD (vCJD), which is caused by the consumption of BSE-contaminated beef products (5, 6) . The cellular form of PrP, PrP C , is a host-encoded, glycophosphatidylinositol (GPI)-anchored neuronal glycoprotein composed of a flexibly disordered N-terminal domain and a predominantly ␣-helical C-terminal domain (7) (8) (9) . During disease, PrP C undergoes a profound conformational change into an aggregation-prone, misfolded conformer termed PrP Sc , which is enriched in ␤-sheet content (10) . The most commonly encountered forms of PrP Sc are partially resistant to degradation by proteases such as proteinase K (PK), which allows differentiation of PrP C and PrP Sc (11) .
Different strains of PrP Sc have been described and can be classified according to the clinical manifestation of disease, the observed patterns of cerebral PrP Sc deposition, the molecular properties of PrP Sc , and the incubation periods upon inoculation into laboratory animals (12) (13) (14) (15) . The strain-specified properties of PrP Sc are enciphered within the conformation of the protein ag-gregates (16, 17) . The transmission of prions from one species to another is usually limited by the so-called "species barrier" (18) . Generally, disease transmission is efficient when PrP Sc and PrP C are from the same species (19) , whereas species mismatches can result in prolonged incubation periods on primary passage, as well as strain adaptation (20) . However, there are several exceptions to this rule, including in the bank vole (BV), which expresses a PrP that can efficiently replicate prions from many different species (21) (22) (23) (24) (25) . In contrast to the species barrier, which reflects differences between PrP Sc and PrP C amino acid sequences, strain barriers are dictated by the conformation of PrP Sc . For instance, vCJD prions are not transmitted well to transgenic (Tg) mice expressing human PrP (HuPrP) despite the identical amino acid sequences of PrP C and PrP Sc (26) . In contrast, vCJD and BSE prions efficiently transmit disease to wild-type (WT) mice (26) (27) (28) (29) (30) (31) , although there are many differences in the amino acid sequences between the recipient mouse and the infecting bovine PrP (BoPrP) or HuPrP. The species and strain barriers are often collectively referred to as "transmission barriers" for prion replication, for which a given PrP C can only replicate a subset of PrP Sc conformations (32, 33) .
Human CJD prions have been successfully transmitted to both primates (34) and guinea pigs (Cavia porcellus) (35) (36) (37) (38) . Efficient transmission of BSE (39, 40) and vCJD (39) prions to guinea pigs has also been reported. The biochemical and neuropathological hallmarks of BSE and vCJD prions were faithfully maintained upon propagation in guinea pigs, suggesting that these animals may be useful for studying these isolates. However, the incubation periods for BSE and vCJD prions upon primary passage in guinea pigs were very long (ϳ450 and ϳ350 days, respectively) (39) , reducing the attractiveness of using guinea pigs for prion bioassays. Furthermore, it is unknown whether the permissiveness of guinea pigs for BSE and vCJD prions is encoded within the sequence of guinea pig PrP (GPPrP) or is due to a distinct feature of guinea pig neurophysiology.
We hypothesized that Tg mice that overexpress GPPrP would, like guinea pigs, be susceptible to BSE and vCJD prions and exhibit abbreviated incubation periods when challenged with these isolates. Therefore, we generated Tg(GPPrP) mice and then inoculated them with BSE, vCJD, and sporadic CJD (sCJD) prions. All inoculated Tg(GPPrP) mice were susceptible to BSE and vCJD prions, and the incubation periods were approximately half of those of guinea pigs, revealing that expression of GPPrP in Tg mice enables relatively rapid propagation of these isolates. These data argue that Tg(GPPrP) mice may be an excellent model for bioassaying BSE and vCJD prions.
MATERIALS AND METHODS
Ethics statement. Mouse husbandry and bioassays were carried out in accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Academies Press, Washington, DC). All animal protocols were approved by the University of California, San Francisco (UCSF), Institutional Animal Care and Use Committee (breeding colony and production of Tg rats and mice [AN084871] and incubation periods of prion and other neurodegenerative diseases [AN084950]). All BSE and vCJD transmission experiments were performed under biosafety level 3 conditions.
Generation of Tg mice. The GPPrP open reading frame was PCR amplified from guinea pig genomic DNA (Zyagen) with the following primers: 5=-CTATATGGATCCACCATGGCAAATGCCGGCTGCTGG CTGC-3= (forward) and 5=-CTATATTCTAGATCATCCCACTATCAG GAAGATCAGG-3= (reverse). The amplified DNA was digested with BamHI and XbaI and then inserted into plasmid pcDNA3 to create plasmid pcDNA3.GPPrP. Following DNA sequence verification, the guinea pig coding sequence was PCR amplified from pcDNA3.GPPrP with flanking SalI restriction sites with the following primers: 5=-CTATATGTCGA CACCATGGCAAATGCCGGCTGC-3= (forward) and 5=-CTATATGTC GACTCATCCCACTATCAGGAAGAT-3= (reverse). The PCR product was then digested with SalI and ligated into a SalI-digested and dephosphorylated cos.Tet cosmid vector (41) , which drives the expression of proteins in the brain by using the Syrian hamster PrP promoter. The transgene cassette was then excised by digestion with NotI, purified by agarose gel electrophoresis, and then microinjected into the pronuclei of fertilized eggs obtained from FVB-Prnp 0/0 mice. Potential founder ani-mals were identified by Southern blotting with a DNA probe specific for the 3= untranslated region of Syrian hamster Prnp and then backcrossed to FVB-Prnp 0/0 mice (42) to confirm germ line transmission of the transgene. Three lines of Tg(GPPrP) mice were obtained: Tg23441, Tg23447, and Tg23454.
Prion isolates. The following prion isolates were used in this study: a human vCJD isolate obtained from a patient brain sample generously provided by Robert Will and James Ironside of the National CJD Surveillance Unit (United Kingdom); BSE prions from the brain of a naturally infected cow (isolate PG31/90) that were passaged four times in Tg mice expressing BoPrP (43); human prions from sCJD patients exhibiting the MM1, MM2, or VV2 disease subtype; and the mouse-passaged scrapie strain RML, which was maintained in WT CD-1 mice. The guinea pigpassaged vCJD isolate was generated by pooling brain homogenates from three clinically ill, vCJD-inoculated guinea pigs, whereas the guinea pigpassaged BSE isolate was created by pooling brain homogenates from four clinically ill, BSE-inoculated guinea pigs (39) . The guinea pig-passaged sCJD sample was generated by pooling the brain homogenates from three clinically ill guinea pigs that had been inoculated with a guinea pig-passaged sCJD isolate (39) , which was kindly provided by Jun Tateishi of Kyushu University in Japan.
Mouse bioassays. Brain homogenates (10% [wt/vol] in calcium-and magnesium-free phosphate-buffered saline [PBS]) were generated with a Precellys 24 bead beater and then diluted to a final concentration of 1% (wt/vol) in 5% (wt/vol) bovine serum albumin. Weanling (ϳ8-week-old) Tg23454 mice were anesthetized with isoflurane and then intracerebrally inoculated in the right parietal lobe with 30 l of diluted brain homogenate with a 27-gauge syringe. The inoculated mice were monitored daily for routine health assessment and checked three times weekly for the development of clinical signs of neurological illness by using the standard diagnostic criteria for assessing prion disease in mice (44) . Mice were euthanized when two or more signs of disease were apparent, and their brains were removed and either fixed in 10% neutral buffered formalin for neuropathological analysis or snap-frozen on dry ice and then stored at Ϫ80°C for biochemical studies.
Enzymatic digestions of proteins. Ten percent (wt/vol) brain homogenates in PBS were generated with a Precellys 24 homogenizer. Samples were treated with 100 g/ml PK for 1 h at 37°C, and then digestions were stopped by adding phenylmethylsulfonyl fluoride to a final concentration of 2 mM, followed by an equal volume of 2ϫ lithium dodecyl sulfate loading buffer. Samples were boiled for 10 min prior to immunoblot analysis. Peptide-N-glycosidase F (PNGase F) digestions were performed according to the manufacturer's protocol (New England BioLabs).
Immunoblotting. Samples were loaded onto 10% NuPAGE gels (Life Technologies) and then subjected to electrophoresis with the 2-(N-morpholino)ethanesulfonic acid buffer system. Proteins were transferred to polyvinylidene difluoride membranes, which were then blocked with blocking buffer (5% [wt/vol] nonfat milk in Tris-buffered saline containing 0.05% [vol/vol] Tween 20 [TBST]) for 1 to 2 h at room temperature. The membranes were then incubated with horseradish peroxidase-conjugated anti-PrP antibody HuM-P (45) for 1 to 2 h at room temperature. Following three washes with TBST, the membranes were developed with an enhanced chemiluminescence detection system (GE Healthcare) and then exposed to X-ray film.
Quantification of transgene expression levels. Protein concentrations in brain homogenates from WT FVB or Tg(GPPrP) mice were determined with the bicinchoninic acid assay (Thermo Scientific). Normalized samples were prepared in 1ϫ NuPAGE loading buffer containing ␤-mercaptoethanol, boiled for 5 min, and then analyzed by immunoblotting as described above. For the Tg(GPPrP) samples, serial dilutions relative to WT FVB mouse brains were made in 1ϫ NuPAGE loading buffer. Relative levels of GPPrP were compared to those of WT MoPrP in FVB mice and expressed as n-fold differences.
Neuropathology. Formalin-fixed brains were embedded in paraffin, and then brain sections (8 m thick) were cut and mounted onto slides.
For each brain, coronal sections were analyzed at four different levels: the striatum, the hippocampus/thalamus, the midbrain, and the cerebellum. Sections were either processed for immunohistochemistry (IHC) or stained directly with hematoxylin and eosin (H&E) to assess vacuolation. For IHC, endogenous tissue peroxidases were first inhibited by incubation in 3% hydrogen peroxide solution (prepared in methanol) for 30 min. Sections were then subjected to hydrolytic autoclaving at 121°C in citrate buffer for 10 min in order to expose protein epitopes. After cooling, slides were blocked with 10% (vol/vol) normal goat serum for 1 h at room temperature and then incubated with anti-PrP mouse monoclonal antibody 3F4 (46) at a dilution of 1:1,000 overnight at 4°C. PrP deposits were visualized with the Vectastain ABC peroxidase kit (Vector Laboratories) and 3-3=-diaminobenzidine. Slides were counterstained with hematoxylin, and photographs were taken with the Axio Imager.A1 microscope (Carl Zeiss). Semiquantitative scoring of spongiform degeneration and PrP Sc deposition in the brains of prion-inoculated mice was performed by assigning scores to different brain regions as follows: 0, no vacuolation/ PrP Sc deposition; 1, mild vacuolation/PrP Sc deposition; 2, moderate vacuolation/PrP Sc deposition; 3, severe vacuolation/PrP Sc deposition. An individual blind to the experimental design conducted all of the neuropathological analyses.
Generation and analysis of PrP Sc structural models. MoPrP, BoPrP, and GPPrP sequence alignments were constructed with Clustal Omega (47) . One hundred structural models of each PrP sequence were produced with the automodel class in MODELLER (48) for each of the ␤-helix (49) and parallel in-register ␤-sheet (PIRIBS) (50) PrP Sc models, as well as for monomeric MoPrP C (PDB code 1AG2) and BoPrP C (PDB code 1DWZ). Identification of hydrogen bonds was performed by using previously reported geometric constraints (51) and implemented with Tcl scripts in visual molecular dynamics (VMD) (52) . Void volumes in the PIRIBS-A models were calculated and visualized with CAVER Analyst 1.0 (53) by utilizing a 0.5-Å sphere radius. All other model visualization and figure preparation was performed with VMD.
RESULTS
GPPrP is polymorphic at codon 62 (which corresponds to codon 71 in mouse PrP [MoPrP] and codon 72 in HuPrP), where either a glycine or a serine residue can be present (39, 54) . The coding sequence for GPPrP with serine at residue 62 was inserted into the cos.Tet vector, which has been widely used to drive the expression of PrP and other transgenes in the brain (41) . Following microinjection into zygotes isolated from PrP knockout mice, we obtained three lines of Tg(GPPrP) mice by germ line transmission, which were designated Tg23441, Tg23447, and Tg23454. Semiquantitative immunoblotting revealed that Tg23441 mice express GPPrP at levels approximately equivalent to those of MoPrP in WT mice, whereas the Tg23447 and Tg23454 lines overexpressed GPPrP at approximately 1.5-and 2.5-fold, respectively, the levels in WT mice ( Fig. 1A ). Since PrP levels appeared to be slightly lower in guinea pigs than in WT mice ( Fig. 1B) , we estimate that Tg23454 mice overexpress GPPrP at approximately 3-fold the level found in guinea pigs.
A portion of PrP C in the brain normally undergoes endoproteolytic processing to produce C-terminal cleavage fragments, referred to as C1 and C2 (55) . In all three lines of Tg(GPPrP) mice, the predominant PrP species that we observed in the brain by immunoblotting was not the diglycosylated full-length species, which was the most abundant PrP species in WT FVB mice ( Fig.  1A) . After removal of the N-linked oligosaccharides from PrP, bands corresponding to full-length and C2 species were apparent (Fig. 1B) . The epitope for the HuM-P antibody used to detect MoPrP and GPPrP encompasses residues 96 to 105 (MoPrP numbering) (45) and therefore does not detect the PrP C1 fragment.
The relative proportions of the PrP C2 fragment were increased following removal of the N-linked sugars in Tg23454 mice and in guinea pigs ( Fig. 1B) , indicating that the predominant PrP band corresponds to the PrP C2 cleavage fragment. Following deglycosylation, full-length GPPrP migrated slightly faster than MoPrP because the sequence of GPPrP differs from that of other mammalian PrPs in that it lacks 10 residues N terminal to the octapeptide repeats in the flexible N-terminal region of the protein (Fig. 2 ) (39) . Interestingly, the PrP C2 fragment in guinea pigs and Tg23454 mice also migrated more rapidly than the mouse C2 fragment, despite the fact that the C2 cleavage site occurs on the C-terminal side of the 10-residue deletion in GPPrP (Fig. 1B) . One possible explanation is that C2 cleavage occurs on the basis of the length of the PrP N-terminal domain instead of in a sequencespecific manner, as has been observed for PrP C1 cleavage (56) .
No signs of spontaneous neurological dysfunction were observed in any of the Tg(GPPrP) lines up to 600 days of age (Table  1) . We did not conduct extensive neuropathological analysis or perform serial transmission experiments to test for the presence of subclinical prion disease. To examine the susceptibility of these Tg lines to prions, we inoculated them with sCJD prions that had been previously passaged twice in guinea pigs (39) . This guinea pig-passaged sCJD isolate was originally derived from an sCJD patient with an unknown disease subtype (37) and was last passaged in guinea pigs that express GPPrP with glycine at codon 62. All three lines of Tg(GPPrP) mice developed prion disease following inoculation with this strain of guinea pig-passaged sCJD pri- ons, with mean incubation periods ranging from 136 to 157 days (Table 1) , which was ϳ100 days shorter than the incubation period of guinea pig-passaged sCJD prions in guinea pigs (39) . Interestingly, there did not appear to be a correlation between the GPPrP expression level in the Tg mice and the resultant incubation period of guinea pig-passaged sCJD prions (Fig. 3A) .
We used the Tg23454 line for the remainder of our transmission studies because these mice expressed the highest levels of GPPrP and exhibited the shortest mean incubation period following inoculation with guinea pig-passaged sCJD prions. Intracerebral inoculation of Tg23454 mice with BSE prions resulted in efficient disease transmission, with a mean incubation period of 210 days, which was ϳ230 days shorter than the corresponding incubation period in guinea pigs ( Table 2) . For these studies, we used BSE prions that had previously been passaged in Tg(BoPrP) mice since the incubation periods of bovine-and Tg(BoPrP)-derived BSE prions in Tg(BoPrP) mice were essentially identical (33) . BSE prions passaged in guinea pigs (39) and Tg23454 mice were injected into Tg23454 mice for serial passaging, and the resulting mean incubation times (ϳ140 days) were similar (Fig. 3B ). Inoculation of Tg23454 mice with brain homogenate from a vCJD patient resulted in a mean incubation period of 199 days, which was ϳ170 days shorter than the incubation period of vCJD prions in guinea pigs ( Table 2 ). Secondary passage of vCJD prions in Tg23454 mice reduced the mean incubation period to 122 days, which was shorter than the mean incubation period (ϳ150 days) of guinea pig-passaged vCJD prions injected into Tg23454 mice (Fig. 3C) . One possible explanation for this discrepancy between incubation periods is that the guinea pig-passaged vCJD sample was isolated from a guinea pig with glycine at codon 62 of PrP (39) , whereas Tg23454 mice express GPPrP with serine at residue 62. These results demonstrate that both BSE and vCJD prions can be efficiently propagated in Tg(GPPrP) mice.
None of the Tg23454 mice that were inoculated with brain homogenate from sCJD patients exhibiting the MM1, MM2, or VV2 disease subtype developed clinical signs of prion disease, suggesting that expression of GPPrP creates a substantial transmission barrier for these strains (Table 3 ) and consistent with the low disease transmission rates observed upon inoculation of guinea pigs with prions from CJD patients (37, 57) . The three sCJD isolates inoculated into Tg23454 mice are distinct from the sCJD isolate originally used to generate the guinea pig-passaged sCJD prions (37) . No signs of disease were observed in Tg23454 mice inoculated with the RML strain of mouse-passaged scrapie prions. Like the Tg23454 mice, guinea pigs were also resistant to infection with RML prions (39) . Since we did not perform neuropatholog- ical analysis or passaging experiments with Tg23454 mice inoculated with sCJD or RML prions, we cannot exclude the presence of subclinical prion disease in these animals. The brains of Tg23454 mice that were inoculated with BSE or vCJD prions exhibited PK-resistant PrP (Fig. 4A) . No PK-resistant PrP was observed in the brain of an uninoculated Tg23454 mouse at 606 days of age, consistent with the absence of clinical signs of spontaneous neurological illness in these animals ( Table  1 ). Distinct strains of prions can be distinguished by the electrophoretic mobility of the unglycosylated PK-resistant PrP fragment on an immunoblot. Type 1 strains migrate to ϳ21 kDa, whereas type 2 strains migrate to ϳ19 kDa (15) . Both BSE and vCJD are classified as type 2 prion strains, and upon primary and secondary propagations in Tg23454 mice, a type 2 PrP Sc signature was observed in the brain (Fig. 4B ). Inoculation of Tg23454 mice with guinea pig-passaged vCJD and BSE prions also produced type 2 PrP Sc (Fig. 4B ). Sporadic CJD prions that have been passaged in guinea pigs exhibit type 1 PrP Sc (39) , and type 1 PrP Sc was found in the brains of Tg23454 mice that had been inoculated with these prions (Fig. 4B) . These results indicate that for BSE and vCJD prions, the strain type was preserved upon propagation in Tg23454 mice, arguing for the maintenance of prion strain fidelity.
A subset of the brains of BSE-and vCJD-inoculated Tg23454 mice was analyzed neuropathologically. Moderate-to-severe spongiform degeneration and PrP Sc deposition were observed in all of the brain regions analyzed, with the exception of the cerebellum ( Fig. 5A and B) . BSE-and vCJD-challenged Tg23454 mice exhibited similar patterns of vacuolation and cerebral PrP Sc deposition, supporting the assertion that BSE and vCJD are caused by the same prion strain (27, 58) . Upon the first passage of BSE prions in Tg23454 mice, prominent loss of CA2 and CA3 neurons was apparent in the hippocampus (Fig. 5C ). In vCJD-inoculated Tg23454 mice, extensive cell loss was observed in all areas of the hippocampus, including the dentate gyrus ( Fig. 5D ). Abundant vacuolation was observed in the cerebral cortex in both BSE-and vCJD-inoculated mice ( Fig. 5E and G) and was accompanied by large, coarse PrP Sc deposits ( Fig. 5F and H) . Large clusters of vacuoles, as well as numerous coarse PrP Sc deposits, were found in the hippocampus in Tg23454 mice upon secondary passage of the vCJD and BSE isolates ( Fig. 5I to L). "Florid" PrP Sc plaques, which are found in the brains of vCJD patients (5), were not observed in the brains of vCJD-inoculated Tg23454 mice. Overall, the neuropathological changes found in the brains of BSE-and vCJD-inoculated Tg23454 mice were similar to those observed in the brains of guinea pigs challenged with the same prion isolates (39) . That GPPrP supports the rapid, faithful propagation of BSE and vCJD prions but not RML prions suggests that sequence differences between MoPrP and GPPrP are responsible for the strain-specific propagation. We therefore searched for potential sequence features of GPPrP that could mediate these differential transmissions by comparing the amino acid sequences of GPPrP, BoPrP, and MoPrP. An alignment of these sequences revealed eight positions that were conserved between the GPPrP and BoPrP sequences but differed in the MoPrP sequence (Fig. 2) . Three of these residues (residues 10, 14, and 17, numbered according to the sequence of MoPrP) are located within the N-terminal signal sequence of PrP and were not considered further. Similarly, residue 231, which occurs at or close to the GPI anchor attachment site, was not investigated because it does not appear in any structural models of PrP C or PrP Sc . At residues 108 and 137, either methionine or leucine residues are present in the three PrP se-quences. However, these conservative amino acid changes are unlikely to lead to any major structural effects. Thus, we focused our analysis on residues 142 (serine in GPPrP and BoPrP, asparagine in MoPrP) and 144 (tyrosine in GPPrP and BoPrP, tryptophan in MoPrP), both of which are located near the N-terminal region of ␣-helix 1 in PrP C . We assessed the impact of these variant residues on the structures of PrP C by generating comparative models of the GPPrP, BoPrP, and MoPrP sequences by using as templates the nuclear magnetic resonance (NMR) structures of MoPrP C (PDB code 2L1H) and BoPrP C (PDB code 1DWZ). Although the structure of PrP Sc is not known, we also generated models of the three PrP sequences by using four of the prevailing structural models of MoPrP Sc : the left-handed ␤-helix model (49) and three PIRIBS models (50) .
Models based on PrP C structures revealed that residues 142 and 144 are both solvent exposed (Fig. 6 ). Only small structural differences were observed among the models when the three sequences were threaded onto the MoPrP C and BoPrP C templates, suggesting that the residue 142 and 144 sequence variants would be predicted to have only a minor influence on the structure of PrP C . Comparative models built from the MoPrP Sc scaffolds, however, suggested that the GPPrP and BoPrP variants at these two residues are incompatible with these MoPrP Sc models. In the ␤-helix model, residue 142 lies at the radial interface between trimers ( Fig. 7A and C) , while residue 144 is positioned at the interface between stacked monomers (Fig. 7B ). In the ␤-helix model, the asparagine side chain of residue 142 in MoPrP participates in a hydrogen bond with the peptide backbone of the adjacent subunit with 78% occupancy. This interaction is observed less frequently in the models generated by using the BoPrP and GPPrP sequences (17 and 8%, respectively), which contain the shorter serine side chain that is less capable of bridging the intermolecular gap to form this interaction (Fig. 7C ). All PIRIBS-based PrP Sc models place residues 142 and 144 on a critical ␤-hairpin loop (residues 127 to 161) that participates in intermolecular interactions among stacked monomers ( Fig. 7D and E) . In particular, the tyrosine present at residue 144 in GPPrP and BoPrP structurally alters this loop in the PIRIBS-A model, with the side chain oriented outside the hairpin, resulting in a large, unfavorable channel penetrating the structure (Fig. 7F ). Notwithstanding the limitations of predictions based on structural models, the above findings offer a plausible basis for why the GPPrP sequence cannot adopt the RML strain structure, as it would cause an unstable void in the framework. Since GPPrP and BoPrP sequences have similar discrepancies threading onto MoPrP Sc models, it is possible that a BSE strain structure is more consistent with the GPPrP sequence.
DISCUSSION
In the studies reported here, we have determined that prions from BSE-afflicted cattle and vCJD patients transmit prion disease with 100% efficiency to Tg mice that express GPPrP, with incubation periods of ϳ200 days, which is about half the time needed to bioassay these strains in guinea pigs. Our results strongly suggest that the heightened susceptibility of guinea pigs to BSE and vCJD prions is mediated by the sequence of GPPrP. It should be noted that the vCJD and BSE bioassays were performed with guinea pigs that express GPPrP with glycine at codon 62, whereas the Tg-(GPPrP) mice used for bioassays express GPPrP with serine at codon 62. Therefore, we cannot exclude the possibility that this polymorphism also influences the replication kinetics of vCJD Immunoblot analysis of PrP in brain homogenates from an uninoculated, asymptomatic Tg23454 mouse at 606 days of age (none); a clinically ill, BSEinoculated Tg23454 mouse at 215 days postinoculation (BSE); and a clinically ill, vCJD-inoculated Tg23454 mouse at 201 days postinoculation (vCJD). Brain homogenates were either digested with PK (ϩ) or left undigested (-). PK-resistant PrP Sc was only observed in the mice inoculated with prions. (B) Immunoblot analysis of PK-resistant PrP Sc in brain homogenates from Tg23454 mice inoculated with the prion isolates indicated. The brains of Tg23454 mice inoculated with BSE prions (first or second passage), guinea pig-passaged BSE prions, vCJD prions (first or second passage), or guinea pig-passaged vCJD prions exhibited type 2 PrP Sc . In contrast, Tg23454 mice inoculated with guinea pig-passaged sCJD prions exhibited type 1 PrP Sc . The incubation period (i.p.) of the mouse from which the brain was taken for immunoblotting is shown below each lane. In both panels, PrP was detected with the antibody HuM-P. Molecular masses of migrated protein standard markers are shown in kilodaltons to the left of each panel. and BSE prions. Furthermore, because BSE and vCJD prions are also transmitted efficiently, but slowly, to non-Tg mice (27, 30) , other mouse-specific factors, such as putative prion replication cofactors (59, 60) , may also play a role.
Tg(GPPrP) mice offer several advantages over guinea pigs for prion bioassays. In addition to the shorter disease incubation periods, mice are easier and cheaper to maintain, and they can be crossed with other Tg lines to permit monitoring of prion replication kinetics by bioluminescence imaging (61), for instance. However, the larger size of guinea pigs may provide unique bioassay benefits in some situations, such as when cerebrospinal fluid or blood sampling is required, or in imaging studies where an increased brain size may reveal additional levels of detail.
Studies of prion strains have been facilitated by the production of Tg mice expressing PrP genes from different species (62) . Generally, incubation periods are shortened in the Tg mice because of the overexpression of PrP. While BSE prions present in either BSE-infected cattle or Tg(BoPrP) mouse brains can be efficiently transmitted to Tg mice expressing BoPrP (33, 43, 45, 58, 63) , the incubation periods are long (ϳ250 days), despite the overexpression of BoPrP. The incubation periods are also long upon the secondary passage of BSE prions in these mice (58) . In contrast, the incubation period for BSE prions in Tg(GPPrP) mice, which overexpress PrP at lower levels than the aforementioned Tg mice expressing BoPrP (ϳ2.5-fold versus ϳ8-fold), was only ϳ210 days upon primary passage and ϳ135 days upon secondary passage. This ϳ75-day decrease in the incubation period upon serial passage suggests that there is a transmission barrier for BSE prions in Tg(GPPrP) mice. However, it should be noted that 100% of the BSE-inoculated Tg(GPPrP) mice developed clinical prion disease, and we observed no evidence of BSE strain adaptation upon serial passage, either by neuropathological analysis of infected brain tissue or by PrP Sc typing. Thus, the somewhat extended incubation period of BSE prions upon primary passage in Tg(GPPrP) mice is likely to result from slower prion replication kinetics, possibly because of the sequence mismatch between BoPrP Sc and GPPrP C , or a difference in the prion titer between the BSE isolate and the Tg(GPPrP)-passaged BSE sample.
Variant CJD prions are transmitted efficiently to Tg mice expressing BoPrP, with incubation periods similar to those observed for BSE prions (ϳ270 days) (33, 58) , as well as to WT mice, with incubation periods of around 370 days (27) . Curiously, the transmission of vCJD prions to Tg mice expressing sequence-matched HuPrP is remarkably inefficient, with only a few mice exhibiting clinical signs of disease following incubation periods of Ͼ600 days (26) . On the basis of the aforementioned results, the propagation of vCJD prions was next studied in Tg mice expressing chimeric Hu/MoPrP molecules. In Tg22372 mice, which express chimeric PrP containing seven HuPrP-specific residues, the mean incubation periods for vCJD prions were 279 to 368 days (64) . Shorter but highly variable incubation periods of vCJD prions (176 to 326 days) were observed in Tg1014 mice, which express chimeric PrP containing six HuPrP-specific residues (65) . However, in both Tg22372 and Tg1014 vCJD-inoculated mice, a mixture of prion strains was apparent, indicative of strain selection or adaptation. In Tg(GPPrP) mice, the incubation period of vCJD prions was ϳ200 days on primary passage and ϳ120 days on secondary passage, and no strain adaptation was apparent by neuropathological and biochemical analyses. It should be noted that the vCJD prion isolates used in the aforementioned studies were not always the same, which complicates accurate comparisons of incubation periods. Collectively, these results argue that GPPrP is a better, more rapid substrate than BoPrP, HuPrP, or chimeric Mo/HuPrP expressed in Tg mice for propagating BSE and vCJD prions with high fidelity.
Several potential features of the GPPrP sequence may give rise to the enhanced BSE and vCJD prion replication kinetics observed. Unlike other mammalian PrPs, GPPrP has a deletion of 10 residues that occurs N terminal to the octapeptide repeat domain (Fig. 2) (39) . However, this region of PrP is thought to be dispensable for prion replication (66, 67) , suggesting that the receptiveness of GPPrP for BSE and vCJD prions is likely to be encoded elsewhere in PrP. Another possibility is that the unique endoproteolytic-processing properties of GPPrP play a role. We found that GPPrP undergoes so-called "␤ cleavage" to produce the C2 PrP endoproteolytic fragment much more efficiently than MoPrP (Fig. 1) . The PrP C2 fragment is similar in molecular weight to the PK-resistant core of PrP Sc , and C2 levels increase dramatically during prion disease (68) . Although Tg mice expressing a C2-like PrP allele are fully susceptible to prions, incubation periods are protracted in these mice, suggesting that the C2 fragment, if anything, delays the kinetics of prion replication (67) . Thus, the increased presence of PrP C2 fragments in Tg(GPPrP) mice is unlikely to be responsible for accelerating the transmission of BSE and vCJD prions.
Structural models generated by threading the sequences of GPPrP and BoPrP onto the ␤-helix and PIRIBS models of Mo-PrP Sc implied that the GPPrP and BoPrP sequences are incompatible with these models. In particular, GPPrP-and BoPrP-specific amino acid residues at positions 142 and 144 are predicted to generate unfavorable structural changes in MoPrP Sc . Interestingly, the predicted structural changes were very similar for the GPPrP and BoPrP sequences, suggesting that these two PrP sequences may be similarly capable of adopting an alternate PrP Sc structure, such as the one present in the BSE and vCJD strains. This may explain why faithful transmission of BSE prions can be readily achieved in Tg(GPPrP) and Tg(BoPrP) mice, whereas the replication of mouse prions, such as the RML strain, is prevented or delayed (69) . Although BSE prions are transmitted efficiently to WT and Tg(MoPrP) mice (43) , serial passaging and strain characterization studies have revealed that mouse-passaged BSE prions exhibit properties vastly different from those of the original BSE strain (31, 58, 70) . Therefore, the structural incompatibility conferred by MoPrP-specific residues at positions 142 and 144 may promote prion strain adaptation upon exposure to BSE prions. It is important to note that the ␤-helix and PIRIBS MoPrP Sc structures that served as templates for the GPPrP Sc and BoPrP Sc structures are themselves models with associated limitations (71) . Thus, insights gained from using these models need to be confirmed experimentally. Our finding that Tg(GPPrP) mice were susceptible to vCJD prions but not sCJD MM1, MM2, or VV2 prions is in contrast to the finding that Tg1014 mice exhibit shorter incubation periods of both vCJD and sCJD MM1 prions than mice expressing WT HuPrP (65) . Interestingly, HuPrP also contains the GPPrP-and BoPrP-specific residues at positions 142 and 144. Thus, a strain barrier conferred by residue 142 and 144 variants, as opposed to a species barrier, may mediate the differential transmission of human prion strains in Tg(GPPrP) mice. These data demonstrating that vCJD and BSE prions are transmitted more rapidly to Tg(GPPrP) mice than to mice expressing HuPrP may also indicate that the HuPrP sequence has evolved to confer resistance to exogenous, as well as endogenous, prion strains (72, 73) .
To the best of our knowledge, Tg23454 mice exhibit the shortest BSE and vCJD prion incubation periods described to date. Although Tg mice expressing BVPrP exhibit BVPrP-adapted vCJD and BSE prion incubation periods of ϳ40 and ϳ60 days, respectively, the incubation periods of both strains upon initial passage were Ͼ300 days (25) . It may be possible to decrease the incubation periods for BSE and vCJD prions further by generating Tg mice that express chimeric Mo/GPPrP molecules, as this strategy has proven highly effective at reducing the incubation periods of sCJD MM1 prions (64, 65) , or by utilizing chimeric Mo/ BVPrPs. Because it has been estimated that 1 out of 2,000 individuals in the United Kingdom may possess abnormal PrP species in the appendix because of BSE exposure (74) , that vCJD can be transmitted by transfusion of contaminated blood (75) (76) (77) , and that prions can be amplified from the blood and urine of vCJD patients (78, 79) , sensitive and rapid bioassays for BSE and vCJD prions will be critical to measuring infectivity levels in biological tissues and to assessing the risk of horizontal vCJD transmission.
